AGA Clinical Practice Update on Diagnosis and Management of Immune Checkpoint Inhibitor Colitis and Hepatitis: Expert Review

Michael Dougan; Yinghong Wang; Alberto Rubio-Tapia; Joseph K. Lim

doi:10.1053/j.gastro.2020.08.063

AGA Clinical Practice Update on Diagnosis and Management of Immune Checkpoint Inhibitor Colitis and Hepatitis: Expert Review

Michael Dougan, Yinghong Wang, Alberto Rubio-Tapia, Joseph K. Lim

Gastroenterology Hepatology & Nutrition

Research output: Contribution to journal › Article › peer-review

113 Scopus citations

Abstract

Background & Aims: Immune checkpoint inhibitors (ICIs) have transformed the treatment landscape for oncology, leading to durable remissions in a subset of patients, but also a broad range of potentially life-threatening inflammatory toxicities, many of which involve the gastrointestinal (GI) tract and liver. The purpose of this expert review was to update gastroenterologists on the gastrointestinal and hepatic toxicities of ICIs and provide best practice advice on their diagnosis and management. Methods: The evidence reviewed in this work combines the expert clinical opinion of the authors with a comprehensive search of several English-language databases and a manual review of relevant publications.

Original language	English (US)
Pages (from-to)	1384-1393
Number of pages	10
Journal	Gastroenterology
Volume	160
Issue number	4
DOIs	https://doi.org/10.1053/j.gastro.2020.08.063
State	Published - Mar 2021

Keywords

Adverse Event
Enterocolitis
Hepatitis
Immune Checkpoint Inhibitor
Toxicity

ASJC Scopus subject areas

Hepatology
Gastroenterology

Access to Document

10.1053/j.gastro.2020.08.063

Cite this

@article{fa0bfd1f81a34fd4b89aac78f522787d,

title = "AGA Clinical Practice Update on Diagnosis and Management of Immune Checkpoint Inhibitor Colitis and Hepatitis: Expert Review",

abstract = "Background & Aims: Immune checkpoint inhibitors (ICIs) have transformed the treatment landscape for oncology, leading to durable remissions in a subset of patients, but also a broad range of potentially life-threatening inflammatory toxicities, many of which involve the gastrointestinal (GI) tract and liver. The purpose of this expert review was to update gastroenterologists on the gastrointestinal and hepatic toxicities of ICIs and provide best practice advice on their diagnosis and management. Methods: The evidence reviewed in this work combines the expert clinical opinion of the authors with a comprehensive search of several English-language databases and a manual review of relevant publications.",

keywords = "Adverse Event, Enterocolitis, Hepatitis, Immune Checkpoint Inhibitor, Toxicity",

author = "Michael Dougan and Yinghong Wang and Alberto Rubio-Tapia and Lim, {Joseph K.}",

note = "Publisher Copyright: {\textcopyright} 2021 AGA Institute",

year = "2021",

month = mar,

doi = "10.1053/j.gastro.2020.08.063",

language = "English (US)",

volume = "160",

pages = "1384--1393",

journal = "Gastroenterology",

issn = "0016-5085",

publisher = "W.B. Saunders Ltd",

number = "4",

}

TY - JOUR

T1 - AGA Clinical Practice Update on Diagnosis and Management of Immune Checkpoint Inhibitor Colitis and Hepatitis

T2 - Expert Review

AU - Dougan, Michael

AU - Wang, Yinghong

AU - Rubio-Tapia, Alberto

AU - Lim, Joseph K.

PY - 2021/3

Y1 - 2021/3

N2 - Background & Aims: Immune checkpoint inhibitors (ICIs) have transformed the treatment landscape for oncology, leading to durable remissions in a subset of patients, but also a broad range of potentially life-threatening inflammatory toxicities, many of which involve the gastrointestinal (GI) tract and liver. The purpose of this expert review was to update gastroenterologists on the gastrointestinal and hepatic toxicities of ICIs and provide best practice advice on their diagnosis and management. Methods: The evidence reviewed in this work combines the expert clinical opinion of the authors with a comprehensive search of several English-language databases and a manual review of relevant publications.

AB - Background & Aims: Immune checkpoint inhibitors (ICIs) have transformed the treatment landscape for oncology, leading to durable remissions in a subset of patients, but also a broad range of potentially life-threatening inflammatory toxicities, many of which involve the gastrointestinal (GI) tract and liver. The purpose of this expert review was to update gastroenterologists on the gastrointestinal and hepatic toxicities of ICIs and provide best practice advice on their diagnosis and management. Methods: The evidence reviewed in this work combines the expert clinical opinion of the authors with a comprehensive search of several English-language databases and a manual review of relevant publications.

KW - Adverse Event

KW - Enterocolitis

KW - Hepatitis

KW - Immune Checkpoint Inhibitor

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=85102123154&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85102123154&partnerID=8YFLogxK

U2 - 10.1053/j.gastro.2020.08.063

DO - 10.1053/j.gastro.2020.08.063

M3 - Article

C2 - 33080231

AN - SCOPUS:85102123154

SN - 0016-5085

VL - 160

SP - 1384

EP - 1393

JO - Gastroenterology

JF - Gastroenterology

IS - 4

ER -

AGA Clinical Practice Update on Diagnosis and Management of Immune Checkpoint Inhibitor Colitis and Hepatitis: Expert Review

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this